2022 Annual Meeting | C158 - Frontotemporal Dementia
Program Materials Program Evaluations
01:00 PM - 01:30 PM PDT | Speaker |
Clinical and Neuropsychological Aspects of FTD
Bradley F. Boeve, MD, FAAN |
01:00 PM - 01:00 PM PDT | Speaker |
Walk-in Slides
Bradley F. Boeve, MD, FAAN |
01:30 PM - 02:00 PM PDT | Speaker |
Neuroimaging Aspects of FTD
Howard J. Rosen, MD |
02:00 PM - 02:30 PM PDT | Speaker |
Management/Treatment Aspects of FTD
Peter A. Ljubenkov, MD |
02:30 PM - 03:00 PM PDT | Discussion |
Open Discussion
Bradley F. Boeve, MD, FAAN, Howard J. Rosen, MD, Peter A. Ljubenkov, MD |
Bradley F. Boeve, MD, FAAN | Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care. |
Howard J. Rosen, MD | Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |
Peter A. Ljubenkov, MD | Dr. Ljubenkov has nothing to disclose. |